The effectiveness of CMS' cost-cutting strategy in Alzheimer's lies in the small number of Medicare-related claims paid for Leqembi, the second FDA-approved therapy in the class. Since July 2023, based on claims data, only a scant 4,000-5,000 patients have started on Leqembi, with approximately 2,000-2,500 patients currently on treatment. This is a fraction of potentially eligible patients.